A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression

Clinical trial NCT05947812 · UNKNOWN

Trial details

NCT number: NCT05947812
Sponsor: 60P Australia Pty Ltd
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

COVID 19 Disease Mild to Moderate COVID 19 Disease SARS-CoV-2 Infectious Disease Severe Acute Respiratory Syndrome Coronavirus 2

Start date: 2023-08-01
Primary completion: 2024-04-27
Enrollment: 148

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.